Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Although p53 inactivation promotes genomic instability and presents a route to malignancy
for more than half of all human cancers,, the patterns through which heterogenous TP53 …

Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …

Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …

Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …

Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …